Congress must protect vital drug patents from Wall Street attacks

N/A by N/A is licensed under N/A N/A
Hedge-fund investors are coming to raid your medicine cabinet.

Cutting-edge treatments for diseases affecting millions of Americans are threatened by Wall Street’s latest moneymaking scheme. The ploy: hedge funds bet against a drug company’s stock price, launch attacks against the firm’s patents on its best-selling medicines and then reap windfall profits when investors panic and the stock price plummets.

Unless Congress protects pharmaceutical-research firms from these assaults, funding for drug discovery will dry up and many new treatments won’t ever make it into the hands of patients.

Hedge-fund manager Kyle Bass pioneered the strategy, which relies on a new legal procedure known as “inter partes review,” or IPR. Earlier this year, Bass — who previously made $590 million betting that homeowners wouldn’t be able to make their mortgage payments during the financial crisis — filed a review against Acorda Therapeutics’ patent on a drug that helps multiple-sclerosis patients walk. The challenge caused Acorda’s share price to crash by 10 percent.

Wall Street began exploiting the system after Congress created the Patent Trial and Appeal Board, a new arm of the Patent Office tasked with taking a second look at patents that some consider too vague. Since its formation in 2013, the board has proven so hungry to annihilate patents that it’s been called a patent “death squad.”

Bass quickly saw how the board was wiping out patents and jumped at the chance to make money from a self-fulfilling prophecy: challenge the patent and short the company’s stock to profit on the market’s reaction.
Article Photo Credit: N/A by N/A is licensed under N/A N/A
Sign Up for Our Email Newsletter

RECENT NEWS

Vaccine Passports Are ‘Reintroducing Politics into the Vaccine Conversation'

Vaccine Passports Are ‘Reintroducing Politics into the Vaccine Conversation'

A vaccine passport is not a get-out-of-pandemic card, but it could feel like one. Former FDA associate commissioner Peter...  Read more

How Covid Has Reframed the 5 Urgencies of 21st Century Healthcare

How Covid Has Reframed the 5 Urgencies of 21st Century Healthcare

...  Read more

J&J vaccine 'safe and effective': Former FDA associate commissioner

J&J vaccine 'safe and effective': Former FDA associate commissioner

CMPI president Peter Pitts weighs in on the pause of the Johnson & Johnson vaccine across the country....  Read more

DRUGWONKS BLOG